ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR(TM) Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

-ATX-01 is the industry's first microRNA therapeutic to be evaluated for DM1 and the first program from ARTHEX's pipeline to enter the clinic -- -First patient expected to be enrolled [...]